Recent

% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

  • tartiaboy tartiaboy May 9, 2013 2:16 PM Flag

    Conference Call

    A lot of rehash, but a couple of key statements.

    Fusilev sales to the clinics remains steady. Very slight decline of approx. 2.5% which could be noise.

    They still expect to meet the revenue guidance which is between $160-$180M for 2013.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Zev down significantly q4 v q1, Fol down sig q4 v q1, Fus down sig q4 v q1....Licensing UP sig Q4 v Q1...If it weren't for the licensing, they would have missed big. Couple this with the lack of transparency and the bomb Raj tossed in March and I can't figure out WHY anyone would stay with this stock and continue to have faith. I was long, now I'm not...I'm not bashing, just stating FACTS. As far as increase cash position, well that can be done many ways with out increasing company value - I was hoping that Z and FOL would be huge this quarter as to start looking for re-entry....It has not happened.

    • very convenient for this unethical guy to keep saying generics will compete amongst themselves and fusilev will grow from its $200m/year, sell his $8.8m stock and then now give guidance of $180m for the overall company.

    • Their statements on the CC have been - understandably - guarded. Looking at the Fusilev wholesaler inventory numbers and the IMS sales data, We should see much better Fusilev sales in the second quarter and steady-state sales for the rest of the year at 75% of pre-competition levels.

      The remainder of the pipeline brought $17.5 million this quarter. That's $70 million per year. Add licensing revenue of about $20 million for the year and you are looking at about $190 million per year.

      If you assume that the sales force can grow current revenue by only 5-10 percent you're looking at $200+ million per year.

      I think Spectrum management is scared to be optimistic in public.

 
SPPI
4.72-0.09(-1.87%)Sep 23 4:00 PMEDT